Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.
1. A compound having the following structure:
wherein, m is 0, 1, 2, 3 or 4;
wherein, n is 1, 2, 3, or 4;
wherein A and B are H;
and wherein
R 1 is selected from
a)
wherein X is oxygen, and
b) an unsymmetrical amine group of the formula
wherein R 3 and R 4 are independently selected from H, a C 1 -C 8 branched alkyl, and a C 1 -C 8 linear alkyl; and
a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein R 1 is
3. The compound of claim 1 , wherein n is 1, m is 0, and R 1 is
4. The compound of claim 1 , wherein n is 2, m is 0, R 1 is
5. The compound of claim 1 , wherein n is 3, m is 0, and R 1 is
6. The compound of claim 1 , wherein n is 2.
7. The compound of claim 1 , wherein n is 3.
8. The compound of claim 1 , wherein n is 4.
9. The compound of claim 1 , wherein R 1 is an unsymmetrical amine group.
10. The compound of claim 1 , wherein R 1 is
11. The compound of claim 1 , wherein n is 1, m is 0, and R 1 is
12. The compound of claim 1 , wherein n is 2, m is 0, and R 1 is
13. A pharmaceutical formulation comprising:
an effective amount of a compound with the following structure:
wherein, m is 0, 1, 2, 3 or 4;
wherein, n is 1, 2, 3, or 4;
wherein A and B are H;
and wherein
R 1 is selected from
a)
wherein X is oxygen and
b) an unsymmetrical amine group of the formula
wherein R 3 and R 4 are independently selected from H, a C 1 -C 8 branched alkyl, and a C 1 -C 8 linear alkyl; and
a pharmaceutically acceptable salt thereof;
and a pharmaceutically acceptable carrier.
14. The pharmaceutical formulation of claim 13 , wherein R 1 is
15. The pharmaceutical formulation of claim 13 , wherein n is 1, m is 0, and R 1 is
16. The pharmaceutical formulation of claim 13 , wherein n is 2, m is 0, and R 1 is
17. The pharmaceutical formulation of claim 13 , wherein n is 3, m is 0 and R 1 is
18. The pharmaceutical formulation of claim 13 , wherein n is 2.
19. The pharmaceutical formulation of claim 13 , wherein n is 3.
20. The pharmaceutical formulation of claim 13 , wherein n is 4.
21. The pharmaceutical formulation of claim 13 , wherein R 1 is an unsymmetrical amine group.
22. The pharmaceutical formulation of claim 13 , wherein R 1 is
23. The pharmaceutical formulation of claim 13 , wherein n is 1, m is 0, and R 1 is
24. The pharmaceutical formulation of claim 13 , wherein n is 2, m is 0, and R 1 is